v3.25.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities      
Net loss $ (96,915) $ (82,842) $ (53,091)
Adjustments to reconcile net loss to net cash used in operations:      
Depreciation and amortization 6,920 7,864 2,246
Bargain purchase gain, net of tax (1,669)
Loss (gain) on disposal of fixed assets 143 (34)
Unrealized loss on derivative liability 8,866
Impairment of intangible assets 4,181
Impairment of operating lease right-of-use assets 405
Impairment of property and equipment 12 64
Inventory write-downs 2,045 76 87
Amortization of debt discount and issuance costs on notes payable 4,382
Share-based compensation expense 11,535 16,141 15,461
Net accretion of premium on short-term investments (951) (1,275) 21
Change in:      
Accounts receivable 23 (949)
Inventory (495) (892) (168)
Other current and non-current assets 85 (2,096) (217)
Accounts payable (1,139) 942 (1,737)
Accrued liabilities (6,098) 6,571 888
Contract liabilities and other current liabilities (188) (6,452) (293)
Operating lease liabilities (2,491) (2,500) (1,280)
Other long-term liabilities 1,152 13
Net cash used in operating activities (68,540) (67,090) (38,019)
Cash flows from investing activities      
Sales of investment securities 35,411 76,700 60,576
Purchases of investment securities (26,065) (41,710) (90,158)
Advance to Ibeo (4,132)
Cash paid for Ibeo business combination (6,300) (11,233)
Purchases of property and equipment (374) (1,935) (4,359)
Net cash provided by (used in) investing activities 2,672 21,822 (38,073)
Cash flows from financing activities      
Principal payments under finance leases (21) (26)
Principal payments under notes payable (392)
Principal proceeds from notes payable, net of debt discount and issuance costs 38,080
Proceeds from stock option exercises 62 175 726
Net proceeds from issuance of common stock 34,748 72,284 13,999
Net cash provided by financing activities 72,890 72,438 14,307
Effect of exchange rate changes on cash and cash equivalents and restricted cash (166) 267
Change in cash, cash equivalents, and restricted cash 6,856 27,437 (61,785)
Cash, cash equivalents, and restricted cash at beginning of period 49,391 21,954 83,739
Cash, cash equivalents, and restricted cash at end of period 56,247 49,391 21,954
Supplemental schedule of non-cash investing and financing activities      
Common stock issued in conversion of note payable 3,745
Non-cash additions to property and equipment 764
Amounts issued to escrow for acquisition consideration 6,300
Acquisition of right-of-use asset 5,395 1,338 10,184
Accrued financing fees (32)
Foreign currency translation adjustments (210) 184
Unrealized (gain) loss on investment securities, available-for-sale $ 153 $ (108)

Source

HTML PDF
ZIP